NeoStem To Present at Rodman & Renshaw Annual China Investment Conference on Tuesday, March 8

NEW YORK, March 7, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Ian Zhang, PhD, MBA, President and Managing Director of NeoStem (China), Inc. will present at the Rodman & Renshaw Annual China Investment Conference on Tuesday, March 8, 2011. The Conference, which runs from March 6 – 8, 2011, is being held at Le Royal Meridien Shanghai, at 789 Nanjing Road East in Shanghai, China, and Dr. Zhang will speak from 11:30 to 11:55 AM Beijing Time in Parlour V.

Dr. Ian Zhang will discuss NeoStem's operations in China and development strategy going forward.  In 2010, the Company began generating revenues from its stem cell-based regenerative medicine therapies, a key element of its growth strategy in both the United States and China. This effort began through a collaboration with Wendeng Hospital in China.  Patients now have the opportunity to access the latest technology from the US in the treatment of a range of orthopedic conditions. Ongoing commercialization of NeoStem's licensed orthopedic applications at Wendeng Hospital is being facilitated by the local government's approval of pricing and reimbursement for these therapies. Patients are eligible for reimbursement of up to 80% of the cost of the  procedure. NeoStem continues to expand its collaborations, recently adding Shijiazhuang Third Hospital in Hebei Province in December, 2010.

Dr. Ian Zhang said, "I look forward to meeting with the Chinese investment community and raising awareness regarding NeoStem's progress in China. Additionally, we are working closely with our newly acquired subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized cell therapy services and development company that, through its cGMP certified manufacturing facilities and team of professionals, facilitates the preclinical and clinical development and eventual commercialization of cellular therapies for clients in the United States, to offer these services in China which will be available with the completion of NeoStem's Beijing laboratory.  NeoStem China plans to add service lines and revenues through both cell banking and cell therapeutics, positioning us well to take advantage of the ongoing paradigm shift towards cell-based medicine." 

About NeoStem, Inc.

NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company.  NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.  The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.

For more information, please visit: http://www.neostem.com.

About Rodman & Renshaw

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005.

For more information visit Rodman & Renshaw on the Internet at www.rodm.com. For more information on the Rodman & Renshaw Annual China Investment Conference visit http://www.rodmanandrenshaw.com/conferences?id=61.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability of PCT's business to complement NeoStem's adult stem cell operations and successful execution of the Company's strategy, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A filed with the Securities and Exchange Commission on December 3, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.  NeoStem may experience difficulties in integrating PCT's business and could fail to realize potential benefits of the merger.  Acquisitions may entail numerous risks for NeoStem, including difficulties in assimilating acquired operations, technologies or products, including the loss of key employees from acquired businesses.

SOURCE NeoStem, Inc.